Corrigendum: Cardioprotective effects of Qishenyiqi mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin-converting enzyme 2 (Evidence-based Complementary and Alternative Medicine (2012) 2012 (978127) DOI: 10.1155/2012/978127);Cardioprotective effects of Qishenyiqi mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin-converting enzyme 2

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Wang, Yong ^a   Li, Chun ^a   Ouyang, Yulin ^a   Yu, Junda ^a   Guo, Shuzhen ^a   Liu, Zhongyang ^b   Li, Dong ^b   Han, Jing ^a   Wang, Wei ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; CHINESE DRUG; FOSINOPRIL; GELATINASE B; QISHENYIQI; RENIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ECHOCARDIOGRAPHY; HEART; HEART EJECTION FRACTION; HEART FUNCTION; HEART PROTECTION; ISCHEMIC HEART DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 84871444757     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2019/9791436     Document Type: Erratum

References (24)

1. He J., Gu D., Wu X., Reynolds K., Duan X., Yao C., Wang J., Chen C.-S., Chen J., Wildman R. P., Klag M. J., Whelton P. K., Major causes of death among men and women in China. The New England Journal of Medicine 2005 353 11 1124 1134 2-s2.0-24944542337 10.1056/NEJMsa050467 (Pubitemid 41317435)
2. Hong C., Wang Y., Lou J., Liu Q., Qu H., Cheng Y., Analysis of myocardial proteomic alteration after Qishenyiqi formula treatment in acute infarcted rat hearts. Zhongguo Zhongyao Zazhi 2009 34 8 1018 1021 2-s2.0-67650523662
3. Dai G. H., Zhang B. L., Guo Z. X., Application of central randomized system in project of clinical trial for secondary prevention of myocardial infarction by Qishen Yiqi Drop Pill. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007 27 7 653 656 2-s2.0-58149099616
4. Yang L., Qi Q., Ke-xu Y., Effects of Yixin Jiedu Decoction on hemodynamic in Ameroid narrow ring caused. Chinese Journal of Traditional Chinese Medicine 2012 05 1280 1282
5. Wang Y., Liu Z., Li C., Li D., Ouyang Y., Yu J., Guo S., He F., Wang W., Drug target prediction based on the herbs components: the study on the multitargets pharmacological mechanism of Qishenkeli acting on the coronary heart disease. Evidence-Based Complementary and Alternative Medicine 2012 2012 10 698531 2-s2.0-84859770257 10.1155/2012/698531
6. Basile J., Toth P. P., Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. Southern Medical Journal 2009 102 10, supplement S1 S12 2-s2.0-74049140052 10.1097/SMJ.0b013e3181ba0d8a
7. Berl T., Renal protection by inhibition of the renin-angiotensin- aldosterone system. Journal of the Renin-Angiotensin-Aldosterone System 2009 10 1 1 8 2-s2.0-67650468721 10.1177/1470320309102747
8. Pinto Y. M., De Smet B. G. J. L., Van Gilst W. H., Scholtens E., Monnink S., De Graeff P. A., Wesseling H., Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovascular Research 1993 27 11 1933 1938 2-s2.0-0027425285 (Pubitemid 23357335)
9. De Gasparo M., Catt K. J., Inagami T., Wright J. W., Unger T., International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacological Reviews 2000 52 3 415 472 2-s2.0-0033824138
10. Billet S., Aguilar F., Baudry C., Clauser E., Role of angiotensin II AT1 receptor activation in cardiovascular diseases. Kidney International 2008 74 11 1379 1384 2-s2.0-56549117604 10.1038/ki.2008.358
11. Zhao Y. X., Yin H. Q., Yu Q. T., Qiao Y., Dai H. Y., Zhang M. X., Zhang L., Liu Y. F., Wang L. C., Liu D. S., Deng B. P., Zhang Y. H., Pan C. M., Song H. D., Qu X., Jiang H., Liu C. X., Lu X. T., Liu B., Gao F., Dong B., ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Human Gene Therapy 2010 21 11 1545 1554 2-s2.0-78649337583 10.1089/hum.2009.160
12. Pfeffer J. M., Pfeffer M. A., Braunwald E., Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circulation Research 1985 57 1 84 95 2-s2.0-0021968215 (Pubitemid 15238844)
13. Pfeffer M. A., Braunwald E., Moye L. A., Basta L., Brown E. J., Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C., Klein M., Lamas G. A., Packer M., Rouleau J., Rouleau J. L., Rutherford J., Wertheimer J. H., Hawkins C. M., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction-Results of the survival and ventricular enlargement trial. The New England Journal of Medicine 1992 327 10 669 677 2-s2.0-0026786643
14. Greenberg B., Quinones M. A., Koilpillai C., Limacher M., Shindler D., Benedict C., Shelton B., Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995 91 10 2573 2581 2-s2.0-0029050016
15. Willenheimer R., Dahlöf B., Rydberg E., Erhardt L., AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. European Heart Journal 1999 20 14 997 1008 2-s2.0-0033159126 10.1053/euhj.1999.1547 (Pubitemid 29306782)
16. Barbe F., Su J. B., Guyene T. T., Crozatier B., Ménard J., Hittinger L., Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure. American Journal of Physiology 1996 270 6 H1985 H1992 2-s2.0-0346496378
17. Rousseau M. F., Konstam M. A., Benedict C. R., Donckier J., Galanti L., Melin J., Kinan D., Ahn S., Ketelslegers J. M., Pouleur H., Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. American Journal of Cardiology 1994 73 7 488 493 2-s2.0-0028258564 10.1016/0002-9149(94)90680-7
18. Kassiri Z., Zhong J., Guo D., Basu R., Wang X., Liu P. P., Scholey J. W., Penninger J. M., Oudit G. Y., Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circulation 2009 2 5 446 455 2-s2.0-70350457666 10.1161/ CIRCHEARTFAILURE.108.840124
19. Mehta P. K., Griendling K. K., Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. American Journal of Physiology 2007 292 1 C82 C97 2-s2.0-33846362954 10.1152/ajpcell. 00287.2006 (Pubitemid 46127306)
20. Qi Y., Li H., Shenoy V., Li Q., Wong F., Zhang L., Raizada M. K., Sumners C., Katovich M. J., Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury. Experimental Physiology 2012 97 1 89 101 2-s2.0-84355162846 10.1113/expphysiol.2011.060673
21. Matsubara H., Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circulation Research 1998 83 12 1182 1191 2-s2.0-0032576551 (Pubitemid 29006033)
22. Chatterjee A., Mir S. A., Dutta D., Mitra A., Pathak K., Sarkar S., Analysis of p53 and NF- B signaling in modulating the cardiomyocyte fate during hypertrophy. Journal of Cellular Physiology 2011 226 10 2543 2554 2-s2.0-79960675340 10.1002/jcp.22599
23. Tang W. H. W., Parameswaran A. C., Maroo A. P., Francis G. S., Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clinic Proceedings 2005 80 12 1623 1630 2-s2.0-28544447015 (Pubitemid 41747065)
24. Hase T., Tanaka H., Suzuki Y., Nakagawa S., Kitano H., Structure of protein interaction networks and their implications on drug design. PLoS Computational Biology 2009 5 10 2-s2.0-73549090972 10.1371/journal.pcbi.1000550 e1000550